Understanding and controlling hepatobiliary function

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 16, Issue 6, 2002, Pages 1025-1034

  Oude Elferink, Ronald P J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ABC transporters; Bile; Cholestasis; Transport

Indexed keywords

ABC TRANSPORTER; BILE SALT; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DEXAMETHASONE; GLYCOPROTEIN P; HYPERFORIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; RIFAMPICIN; RITONAVIR; CHOLESTEROL; CYTOCHROME; DIGOXIN; ELACRIDAR; LIVER X RECEPTOR; PHOSPHATIDYLCHOLINE; RETINOIC ACID; RETINOID; TOPOTECAN; VECURONIUM;

BILE; BILE SECRETION; CHOLESTASIS; DRUG ELIMINATION; DRUG INDUSTRY; DUBIN JOHNSON SYNDROME; FLUID TRANSPORT; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; HEPATOBILIARY SYSTEM; HUMAN; KNOCKOUT MOUSE; MEDICAL RESEARCH; MOUSE; NONHUMAN; PHARMACOKINETICS; PREDICTION; PROTEIN FUNCTION; REVIEW; BLOOD BRAIN BARRIER; CHROMOSOME 18Q; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENTERITIS; FAMILIAL DISEASE; GENE EXPRESSION; INTESTINE EPITHELIUM; INTRAHEPATIC CHOLESTASIS; INTRAHEPATIC CHOLESTASIS TYPE 1; INTRAHEPATIC CHOLESTASIS TYPE 2; INTRAHEPATIC CHOLESTASIS TYPE 3; LIPID BILE LEVEL; PROTEIN EXPRESSION; ANIMAL; ENTEROHEPATIC CIRCULATION; GENETICS; LIVER; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BILIARY TRACT; CHOLESTASIS, INTRAHEPATIC; ENTEROHEPATIC CIRCULATION; HUMANS; LIVER; MICE; MICE, KNOCKOUT;

EID: 0036885588     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0340     Document Type: Article

References (49)

1. Borst, P, & Elferink, R O (2002). Mammalian abc transporters in health and disease. Annual Review of Biochemistry, 71 537-592.
2. Schinkel, A H, Wagenaar, E, Mol, C A, & van Deemter, L (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation, 97 2517-2524.
3. Schinkel, A H, Mayer, U, & Wagenaar, E et al. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proceedings of the National Academy of Sciences of the USA, 94 4028-4033.
4. Smit, J W, Schinkel, A H, Weert, B, & Meijer, D K (1998). Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. British Journal of Pharmacology, 124 416-424.
5. Smit, J W, Schinkel, A H, & Muller, M et al. (1998). Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology, 27 1056-1063.
6. Hoffmeyer, S, Burk, O, & von Richter, O et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences of the USA, 97 3473-3478.
7. Cascorbi, I, Gerloff, T, & Johne, A et al. (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clinical Pharmacology and Therapeutics, 69 169-174.
8. Lown, K S, Mayo, R R, & Leichtman, A B et al. (1997). Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology and Therapeutics, 62 248-260.
9. Panwala, C M, Jones, J C, & Viney, J L (1998). A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. Journal of Immunology, 161 5733-5744.
10. Paulusma, C C, Bosma, P J, & Zaman, G J et al. (1996). Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science, 271 1126-1128.
11. Buchler, M, Konig, J, & Brom, M et al. (1996). cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. Journal of Biological Chemistry, 271 15091-15098.
12. Konig, J, Nies, A T, & Cui, Y H (1999). Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochimica et Biophysica Acta - Biomembranes, 1461 377-394.
13. Keppler, D, & Konig, J (2000). Hepatic secretion of conjugated drugs and endogenous substances. Seminars in Liver Disease, 20 265-272.
14. Loe, D W, Deeley, R G, & Cole, S P (1998). Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Research, 58 5130-5136.
15. Dietrich, C G, de Waart, D R, & Ottenhoff, R et al. (2001). Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Molecular Pharmacology, 59 974-980.
16. Doyle, L A, Yang, W, & Abruzzo, L V et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences of the USA, 95 15665-15670.
17. Maliepaard, M, Scheffer, G L, & Faneyte, I F et al. (2001). Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Research, 61 3458-3464.
18. Jonker, J W, Smit, J W, & Brinkuis, R F et al. (2000). Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of the National Cancer Institute, 92 1651-1656.
19. Wang, R, Salem, M, & Yousef, I M et al. (2001). Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proceedings of the National Academy of Sciences of the USA, 98 2011-2016.
20. Smit, J JM, Schinkel, A H, & Oude Elferink, R PJ et al. (1993). Homozygous disruption of the murine mdr2P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell, 75 451-462.
21. Ruetz, S, & Gros, P (1994). Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell, 77 1071-1082.
22. Smith, A J, Timmermans-Hereijgers, J LPM, & Roelofsen, B et al. (1994). The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Letters, 354 263-266.
23. van Helvoort, A, Smith, A J, & Sprong, H et al. (1996). MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell, 87 507-517.
24. Oude Elferink, R P, Tytgat, G N, & Groen, A K (1997). Hepatic canalicular membrane. 1. The role of mdr2 P-glycoprotein in hepatobiliary lipid transport. FASEB Journal, 11 19-28.
25. Carlton, V EH, Knisely, A S, & Freimer, N B (1995). Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q22, the benign recurrent intrahepatic cholestasis region. Human Molecular Genetics, 4 1049-1053.
26. Bull, L N, van Eijk, M J, & Pawlikowska, L et al. (1998). A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nature Genetics, 18 219-224.
27. Eppens, E F, van Mil, S WC, & de Vree, J M et al. (2001). FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the canalicular membrane of the hepatocyte. Journal of Hepatology, 35 436-443.
28. Ujhazy, P, Ortiz, D, & Misra, S et al. (2001). Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology, 34 768-775.
29. Whitington, P F, & Whitington, G L (1988). Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology, 95 130-136.
30. Emond, J C, & Whitington, P F (1995). Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease). Journal of Pediatric Surgery, 30 1635-1641.
31. Ismail, H, Kalicinski, P, & Markiewicz, M et al. (1999). Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatric Transplantation, 3 219-224.
32. Ng, V L, Ryckman, F C, & Porta, G et al. (2000). Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. Journal of Pediatric Gastroenterology and Nutrition, 30 152-156.
33. Strautnieks, S S, Kagalwalla, A F, & Tanner, M S et al. (1997). Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. American Journal of Human Genetics, 61 630-633.
34. Strautnieks, S S, Bull, L N, & Knisely, A S (1998). A gene encoding a liver-specific abc transporter is mutated in progressive familial intrahepatic cholestasis. Nature Genetics, 20 233-238.
35. Gerloff, T, Stieger, B, & Hagenbuch, B et al. (1998). The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. Journal of Biological Chemistry, 273 10046-10050.
36. Noe, J, Hagenbuch, B, Meier, P J, & St-Pierre, M V (2001). Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology, 33 1223-1231.
37. Strautnieks, S, S, Byrne, J, Soler, A,et al. Progressive familial intrahepatic cholestasis: mutation analysis and evidence for a third locus, 2001, 184
38. Deleuze, J F, Jacquemin, E, & Dubuisson, C et al. (1996). Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology, 23 904-908.
39. Jacquemin, E, de Vree, J ML, & Cresteil, D et al. (2001). The wide spectrum of MDR3 deficiency in patients with progressive familial intrahepatic cholestasis type 3: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology, 120 1448-1458.
40. de Vree, J M, Jacquemin, E, & Sturm, E et al. (1998). Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proceedings of the National Academy of Sciences of the USA, 95 282-287.
41. Van Nieuwkerk, C M, OudeElferink, R P, & Groen, A K et al. (1996). Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdrP-glycoprotein gene. Gastroenterology, 111 165-171.
42. van Nieuwkerk, C M, Groen, A K, & Ottenhoff, R et al. (1997). The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females. Journal of Hepatology, 26 138-145.
43. Muller, M (2000). Transcriptional control of hepatocanalicular transporter gene expression. Seminars in Liver Disease, 20 323-337.
44. Karpen, S (2002). Nuclear receptor regulation of hepatic function. Journal of Hepatology,(in press).
45. Synold, T W, Dussault, I, & Forman, B M (2001). The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Medicine, 7 584-590.
46. Jacquemin, E, Cresteil, D, & Manouvrier, S et al. (1999). Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet, 353 210-211.
47. Lindberg, M C (1992). Hepatobiliary complications of oral contraceptives. Journal of General Internal Medicine, 7 199-209.
48. Rosmorduc, O, Hermelin, B, & Poupon, R (2001). MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology, 120 1459-1467.
49. Thompson, RJ, SS, Gerred, S, Kniseley, A, et al. Adult onset cholangiopathy (AMA -ve PBC) due to mutations in ABCB4, 2001, 184